Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors

Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma

(2009) A. Broniscer et al.   CLINICAL CANCER RESEARCH

EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

(2009) D. A. Bax et al.   CLINICAL CANCER RESEARCH

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

(2009) Fabienne Thomas et al.   EUROPEAN JOURNAL OF CANCER

Protein Expression of Platelet-Derived Growth Factor Receptor Correlates with Malignant Histology and PTEN with Survival in Childhood Gliomas

(2008) H. K. Thorarinsdottir et al.   CLINICAL CANCER RESEARCH

EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts

(2008) Birgit Geoerger et al.   INTERNATIONAL JOURNAL OF CANCER

Chemotherapy for Malignant Brain Tumors of Childhood

(2008) Nicholas G. Gottardo et al.   JOURNAL OF CHILD NEUROLOGY

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

(2008) Regina I. Jakacki et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

(2008) Michael D. Prados et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

(2008) J. F. de Groot et al.   JOURNAL OF NEURO-ONCOLOGY